Biogen (NASDAQ:BIIB – Get Free Report) had its price objective boosted by equities researchers at HSBC from $339.00 to $342.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HSBC’s price target would indicate a potential upside of 57.23% […]
Summit Global Investments purchased a new stake in Biogen Inc. (NASDAQ:BIIB – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,088 shares of the biotechnology company’s stock, valued at approximately $1,575,000. Several other institutional investors have also recently made changes to […]
Summit Global Investments bought a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 6,088 shares of the biotechnology company’s stock, valued at approximately $1,575,000. Several other large investors also recently bought and sold shares of BIIB. International Assets […]
Oppenheimer reissued their outperform rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $270.00 target price on the biotechnology company’s stock. Several other research analysts have also recently weighed in on the stock. Truist Financial reiterated a buy rating […]
Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twenty-seven brokerages that are currently covering the firm, MarketBeat reports. Nine research analysts have rated the stock with a hold recommendation and eighteen have given a buy recommendation to the company. The average 1 year price objective […]